Free shipping on all orders over $ 500

Ralimetinib dimesylate

Cat. No. M2318

All AbMole products are for research use only, cannot be used for human consumption.

Ralimetinib dimesylate Structure
Synonym:

LY2228820 dimesylate; LY2228820 2MsOH

Size Price Availability Quantity
1mg USD 35 In stock
1mg USD 35 In stock
2mg USD 55 In stock
5mg USD 85 In stock
10mg USD 140 In stock
50mg USD 310 In stock
100mg USD 480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ralimetinib dimesylate (LY2228820 dimesylate) is a novel and potent p38MAPK inhibitor. In vitro kinase enzyme activity showed that the IC50 for p38αMAPK and p38βMAPK of LY2228820 were 7 nM and 3 nM, respectively. Phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, was significantly inhibited by LY in both MM cell lines and LT-BMSCs.

Customer Product Validations & Biological Datas
Source Oncotarget (2016). Figure 3. LY2228820
Method colony assays
Cell Lines MDA-MB-231 cells
Concentrations 10 μM
Incubation Time 72 h
Results The triple combination significantly retarded shortterm proliferation of MDA-MB-231 cells compared to vehicle and single drug controls (p<0.001), as well as the two-agent combinations
Chemical Information
Molecular Weight 612.74
Formula C24H29FN6.2CH4O3S
CAS Number 862507-23-1
Solubility (25°C) DMSO 30 mg/mL
Water 33 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Ann-Kathrin Reuschl, et al. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

[2] J Biau, et al. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma

[3] Jian Wang, et al. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

[4] Ronggao Chen, et al. LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells

[5] Robert M Campbell, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Related p38 MAPK Products
BIRB796

BIRB 796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK with Kd of 100pM.

Selonsertib

GS-4997 is a highly selective and potent once-daily oral ASK1 inhibitor with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.

Adezmapimod

Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM.

SB 202190

SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase with IC50 values of 50 and 100 nM inhibiting p38α and p38β, respectively.

PH-797804

PH-797804 is a highly selective and potent inhibitor of p38 MAP kinase with IC50 of 26 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ralimetinib dimesylate, LY2228820 dimesylate; LY2228820 2MsOH supplier, p38 MAPK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.